A detailed history of Lazard Asset Management LLC transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Lazard Asset Management LLC holds 39,441 shares of TRDA stock, worth $692,583. This represents 0.0% of its overall portfolio holdings.

Number of Shares
39,441
Previous 3,082 1179.72%
Holding current value
$692,583
Previous $43,000 1365.12%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$13.65 - $17.86 $496,300 - $649,371
36,359 Added 1179.72%
39,441 $630,000
Q2 2024

Aug 14, 2024

BUY
$11.85 - $16.45 $34,447 - $47,820
2,907 Added 1661.14%
3,082 $43,000
Q1 2024

May 14, 2024

SELL
$11.58 - $17.0 $28,868 - $42,381
-2,493 Reduced 93.44%
175 $2,000
Q4 2023

Feb 14, 2024

BUY
$11.36 - $16.99 $30,308 - $45,329
2,668 New
2,668 $40,000
Q2 2023

Aug 14, 2023

BUY
$11.02 - $18.01 $26,635 - $43,530
2,417 New
2,417 $36,000

Others Institutions Holding TRDA

About Entrada Therapeutics, Inc.


  • Ticker TRDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,368,500
  • Market Cap $551M
  • Description
  • Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...
More about TRDA
Track This Portfolio

Track Lazard Asset Management LLC Portfolio

Follow Lazard Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lazard Asset Management LLC with notifications on news.